Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer

Human Pathology

Volumn 38, Issue 6, 2007, Pages 926-934

  Sassen, Stefanie ^a   Schmalfeldt, Barbara ^a   Avril, Norbert ^a   Kuhn, Walther ^a   Busch, Raymonde ^a   Höfler, Heinz ^a   Fend, Falko ^a   Nährig, Jörg ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Histopathology; Neoadjuvant; Ovarian cancer; Regression; Treatment response

Indexed keywords

CARBOPLATIN; HEMOSIDERIN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GIANT CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATORY CELL; MACROPHAGE; MULTIPLE CYCLE TREATMENT; NECROSIS; OVARY CANCER; PSAMMOMA BODY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR CELL; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 34248232432     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2006.12.008     Document Type: Article

References (35)

1. Cannistra S.A. Cancer of the ovary. N Engl J Med 351 (2004) 2519-2529
2. Piccart M.J., Bertelsen K., James K., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92 (2000) 699-708
3. Vergote I., De Wever I., Tjalma W., et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 71 (1998) 431-436
4. Park T.W., and Kuhn W.C. Neoadjuvant chemotherapy in ovarian cancer. Expert Rev Anticancer Ther 4 (2004) 639-647
5. Kuhn W., Rutke S., Spathe K., et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 92 (2001) 2585-2591
6. Morice P., Dubernard G., Rey A., et al. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J Am Coll Surg 197 (2003) 955-963
7. Vergote I.B., De Wever I., Decloedt J., et al. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Semin Oncol 27 3 Suppl 7 (2000) 31-36
8. Schwartz P.E., Rutherford T.J., Chambers J.T., et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 72 (1999) 93-99
9. Ansquer Y., Leblanc E., Clough K., et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer 91 (2001) 2329-2334
10. Fisher B., Bryant J., Wolmark N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16 (1998) 2672-2685
11. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
12. Avril N., and Weber W.A. Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am 43 (2005) 189-204
13. Weber W.A. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 46 (2005) 983-995
14. Avril N., Sassen S., Schmalfeldt B., et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 23 (2005) 7445-7453
15. Sinn H.P., Schmid H., Junkermann H., et al. Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy. Geburtshilfe Frauenheilkd 54 (1994) 552-558
16. Becker K., Mueller J.D., Schulmacher C., et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98 (2003) 1521-1530
17. Fisher E.R., Wang J., Bryant J., et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 95 (2002) 681-695
18. McCluggage W.G., Lyness R.W., Atkinson R.J., et al. Morphological effects of chemotherapy on ovarian carcinoma. J Clin Pathol 55 (2002) 27-31
19. Moreno A., Escobedo A., Benito E., et al. Pathologic changes related to CMF primary chemotherapy in breast cancer. Pathological evaluation of response predicts clinical outcome. Breast Cancer Res Treat 75 (2002) 119-125
20. Salzer-Kuntschik M., Brand G., and Delling G. Determination of the degree of morphological regression following chemotherapy in malignant bone tumors. Pathologe 4 (1983) 135-141
21. Honkoop A.H., Pinedo H.M., De Jong J.S., et al. Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am J Clin Pathol 107 (1997) 211-218
22. Mandard A.M., Dalibard F., Mandard J.C., et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73 (1994) 2680-2686
23. Evans D.B., Rich T.A., Byrd D.R., et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 127 (1992) 1335-1339
24. Junker K., Thomas M., Schulmann K., et al. Regression grading of neoadjuvant non-small-cell lung carcinoma treatment. Pathologe 18 (1997) 131-140
25. Baldus S.E., Monig S.P., Schroder W., et al. Regression of oesophageal carcinomas after neoadjuvant radiochemotherapy: criteria of the histopathological evaluation. Pathologe 25 (2004) 421-427
26. Junker K. Therapy-induced morphological changes in lung cancer. Pathologe 25 (2004) 475-480
27. S. Kawamoto, B.A. Urban, E.K. Fishman, CT of epithelial ovarian tumors. Radiographics 1999;19 Spec No:S85-102; quiz S263-4.
28. Junker K., Langner K., Klinke F., Bosse U., and Thomas M. Grading of tumor regression in non-small cell lung cancer: morphology and prognosis. Chest 120 (2001) 1584-1591
29. Bonadonna G., Veronesi U., Brambilla C., et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82 (1990) 1539-1545
30. Honkoop A.H., van Diest P.J., de Jong J.S., et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 77 (1998) 621-626
31. Kuerer H.M., Newman L.A., Smith T.L., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17 (1999) 460-469
32. Machiavelli M.R., Romero A.O., Perez J.E., et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 4 (1998) 125-1131
33. Wang E., Ngalame Y., Panelli M.C., et al. Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin Cancer Res 11 (2005) 113-122
34. Wooster R., and Weber B.L. Breast and ovarian cancer. N Engl J Med 348 (2003) 2339-2347
35. Junker K., Muller K.M., Abker S., et al. Cellular changes in non-small cell lung cancer after neoadjuvant therapy. Pathologe 25 (2004) 193-201